Bethesda, MD (May 14, 2021) — Combining minimally invasive endoscopic sleeve gastroplasty (ESG) with the diabetes drug semaglutide can present further important weight reduction for sufferers who are usually not candidates for invasive weight-loss surgical procedure, based on analysis that was chosen for presentation at Digestive Disease Week® (DDW) 2021.
“As the worldwide weight problems charge continues to climb, so do the variety of folks looking for bariatric surgical procedure to deal with their situation,” mentioned Anna Carolina Hoff, MD, lead researcher on the examine and founder and scientific director of Angioskope Brazil, São José dos Campos. “Surgical procedures are a number of the most profitable methods to assist sufferers drop some pounds, however they’ll finally include problems. Our examine exhibits that sufferers could not should endure invasive surgical procedure to get related outcomes.”
In a double-blind examine, researchers randomized 61 sufferers present process ESG into two teams with one group of 29 sufferers receiving semaglutide — an injectable glucagon-like peptide-1 receptor that has been recognized to stimulate weight reduction — starting one month after the process. Another group of 29 sufferers acquired a placebo administered with look-alike injector pens. Three sufferers have been misplaced to follow-up. Participants have been monitored every month for physique weight and physique composition, and blood panels have been taken each three months.
Patients who acquired semaglutide misplaced on common 26.7 p.c of their whole physique weight in comparison with the management group, which on common misplaced 19.6 p.c of whole physique weight. The semaglutide group misplaced 86.3 p.c of their extra weight — the quantity of weight the sufferers wanted to lose to achieve regular BMI — in comparison with 60.4 p.c for the management group. The semaglutide group additionally misplaced 12.7 p.c of their physique fats by weight in comparison with 9 p.c for the management group. Finally, glycated hemoglobin (Hb1Ac) ranges fell 0.95 for the semaglutide group and 0.61 for the controls.
Surgical procedures, similar to laparoscopic sleeve gastrectomy, include elevated prices and the next threat for problems, similar to gastroesophageal reflux illness, or GERD. These surgical procedures are sometimes restricted to these with a BMI of at the very least 35 with comorbidities, or with a BMI above 40. ESG may be carried out at an earlier stage of the illness and at a decrease BMI, so extra sufferers can get the therapy they want earlier than their illness progresses. Treating sufferers with weight problems earlier might help cut back loss of life and comorbidities in addition to cut back prices related to therapies for these situations.
“ESG has been accessible to sufferers for years, nevertheless it has not at all times been as profitable as surgical choices in serving to sufferers drop some pounds,” mentioned Dr. Hoff. “We now have a minimally invasive process that may be simply as profitable when mixed with semaglutide and may be made accessible to much more folks seeking to lose a big quantity of weight.”
ESG is carried out by guiding a tool by means of the affected person’s throat and into the abdomen, the place an endoscopist makes use of sutures to make the abdomen smaller. This helps sufferers drop some pounds by limiting the quantity they’ll eat. Patients are candidates for ESG if they’ve a BMI at or above 30, and food plan and train haven’t helped them drop some pounds, or if they don’t seem to be a candidate for surgical procedure, or don’t want to pursue surgical procedure.
The researchers warning that long run sturdiness of the therapy nonetheless must be decided.
DDW Presentation Details
Dr. Hoff will current information from the examine, “Semaglutide in affiliation to endoscopic sleeve gastroplasty: Taking endoscopic bariatric procedures outcomes to the subsequent stage,” summary Su548, on Sunday, May 23, at 12:15 p.m. EDT. For extra details about featured research, in addition to a schedule of availability for featured researchers, please go to http://www.
###
Digestive Disease Week® (DDW) is the most important worldwide gathering of physicians, researchers and lecturers within the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgical procedure. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is a completely digital assembly from May 21-23, 2021. The assembly showcases greater than 2,000 abstracts and a whole bunch of lectures on the most recent advances in GI analysis, drugs and expertise. More data may be discovered at http://www.
Disclaimer: AAAS and EurekAlert! are usually not accountable for the accuracy of reports releases posted to EurekAlert! by contributing establishments or for using any data by means of the EurekAlert system.
